# US 2004/0082030 A1 · Anti-angiogenic polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082030 A1
- Document ID: US20040082030A1
- Status: Published application
- Kind: A1
- Application number: 10/415,012
- Filed: 2003-04-22
- Published: 2004-04-29
- Earliest claimed: 2000-11-28
- Inventors: David M. Waisman; Geetha Kassam; Mijung Kwon
- Web page: https://patentgrep.com/patent/US20040082030A1

## CPC

- C12N 9/6435: {Plasmin (3.4.21.7), i.e. fibrinolysin}
- A61P 35/00: Antineoplastic agents
- C12Y 304/21007: Plasmin (3.4.21.7), i.e. fibrinolysin
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anti-angiogenic polypeptides A61 or p22 are disclosed. Also disclosed are methods of making the polypeptides and methods of treating subjects having angiogenic diseases or conditions.

## Claims

### Claim 1

An isolated A61 or p22 polypeptide.

### Claim 2 (depends on 1)

The isolated A61 or p22 polypeptide of claim 1 which is a fragment of a mammalian plasminogen and which aligns with human plasminogen as set forth in SEQ ID NO:4, wherein the amino terminal amino acid aligns with Lys-78 of SEQ ID NO:4 and the carboxy terminal amino acid aligns with Lys-180, Lys-468, or Arg-471 of SEQ ID NO:4.

### Claim 3 (depends on 2)

The isolated A61 or p22 polypeptide of claim 2 which has at least 90% sequence identity with SEQ ID NO. 4.

### Claim 4 (depends on 3)

The isolated A61 or p22 polypeptide of claim 3 which comprises at least one free sulfhydryl moiety.

### Claim 5 (depends on 1)

The isolated A61 or p22 polypeptide of claim 1 which is an A61 polypeptide and which inhibits vascular endothelial cell proliferation at an IC50 of no more than 35 nM.

### Claim 6 (depends on 1)

The isolated A61 or p22 polypeptide of claim 1 which is a p22 polypeptide and which inhibits vascular endothelial cell proliferation at an IC50 of no more than 14 nM.

### Claim 7

An isolated polypeptide consisting of 103, 391, or 394 contiguous amino acids of the amino terminal of plasmin.

### Claim 8 (depends on 7)

The isolated polypeptide of claim 7 which is a naturally occurring polypeptide.

### Claim 9 (depends on 8)

The isolated polypeptide of claim 8, wherein the polypeptide has at least 90% sequence identity with the amino terminal of human plasmin as set forth in SEQ ID NO:8.

### Claim 10 (depends on 7)

The isolated polypeptide of claim 7 wherein the plasmin is a human plasmin as set forth in SEQ ID NO:8.

### Claim 11 (depends on 7)

The isolated polypeptide of claim 7, wherein the polypeptide comprises at least one free sulfhydryl moiety.

### Claim 12 (depends on 7)

The isolated polypeptide of claim 7 which is an A61 polypeptide and which inhibits vascular endothelial cell proliferation at an IC50 of no more than 35 nM.

### Claim 13 (depends on 7)

The isolated polypeptide of claim 7 which is a p22 polypeptide and which inhibits vascular endothelial cell proliferation at an IC50 of no more than 14 nM.

### Claim 14

An isolated polypeptide having a sequence as set forth in SEQ ID NO:1, SEQ ID NO: 2, or SEQ ID NO:3 or a conservatively substituted variant thereof.

### Claim 15 (depends on 14)

The isolated polypeptide of claim 14, wherein the polypeptide is a naturally occurring polypeptide.

### Claim 16 (depends on 15)

The isolated polypeptide of claim 15, wherein the polypeptide has at least 90% sequence identity with SEQ ID NO. 4.

### Claim 17 (depends on 14)

The isolated polypeptide of claim 14, wherein the polypeptide comprises at least one free sulfhydryl moiety.

### Claim 18 (depends on 14)

The isolated polypeptide of claim 14 which is an A61 polypeptide and which inhibits vascular endothelial cell proliferation at an IC50 of no more than 35 nM.

### Claim 19 (depends on 18)

The isolated polypeptide of claim 18 which is a p22 polypeptide and which inhibits vascular endothelial cell proliferation at an IC50 of no more than 14 nM.

### Claim 20

An isolated p22 molecule which inhibits vascular endothelial cell proliferation at an IC50 of no more than 14 nM and which has a circular dichroism spectrum having a positive band at about 227.5 nm and a negative band at about 202.7 nm.

### Claim 21

An isolated polypeptide which consists of 391 contiguous amino acids having at least 90% sequence identity with SEQ ID NO: 1; or which consists of 394 contiguous amino acids having at least 90% sequence identity with SEQ ID NO: 2; or which consists of 103 contiguous amino acids having at least 90% sequence identity with SEQ ID NO: 3.

### Claim 22

A conjugate comprising A61 or p22 and a cytotoxic agent.

### Claim 23 (depends on 22)

The conjugate of claim 22 wherein the A61 or p22 is coupled to the cytotoxic agent with a cross-linking agent.

### Claim 24 (depends on 23)

The conjugate of claim 23 wherein the cytotoxic agent is ricin, deoxyribonuclease, diphtheria toxin, pseudomonal exotoxin or ribonuclease.

### Claim 25 (depends on 23)

The conjugate of claim 23, wherein the conjugate is a fusion protein.

### Claim 26

A nucleic acid comprising a first polynucleotide of no more than 1173 nucleotides which encode plasminogen wherein the first polynucleotide encodes a first polypeptide which consists of 391 contiguous amino acids having at least 90% sequence identity with SEQ ID NO: 1; or a second polynucleotide of no more than 1182 nucleotides which encode plasminogen wherein the second polynucleotide encodes a second polypeptide which consists of 394 contiguous amino acids having at least 90% sequence identity with SEQ ID NO: 2; or a third polynucleotide of no more than 309 nucleotides which encode plasminogen wherein the third polynucleotide encodes a third polypeptide which consists of 103 contiguous amino acids having at least 90% sequence identity with SEQ ID NO: 3.

### Claim 27 (depends on 26)

The nucleic acid of claim 26 which encodes SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

### Claim 28 (depends on 26)

A vector comprising the nucleic acid of claim 26.

### Claim 29 (depends on 28)

A eukaryotic or prokaryotic cell comprising the vector of claim 28.

### Claim 30 (depends on 28)

The cell of claim 28, wherein the cell is a mammalian cell.

### Claim 31

A nucleic acid or complement thereto which consists of 309 nucleotides and which has at least 90% sequence identity to SEQ ID NO: 5; or which consists of 1173 nucleotides and which has at least 90% sequence identity to SEQ ID NO: 6; or which consists of 1182 nucleotides and which has at least 90% identity to SEQ ID NO: 7.

### Claim 32 (depends on 31)

The nucleic acid or complement thereto of claim 31 which consists of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7.

### Claim 33

A nucleic acid or complement thereto which consists of 309 nucleotides and which hybridizes under stringent conditions to SEQ ID NO: 5; or which consists of 1173 nucleotides and which hybridizes under stringent conditions to SEQ ID NO: 6; or which consists of 1182 nucleotides and which hybridizes under stringent conditions to SEQ ID NO: 7.

### Claim 34

A method for preparing A61 and/or p22, the method comprising: contacting plasminogen with a vertebrate cell; incubating said cell, thereby producing a product mixture comprising A61, and/or p22; and isolating A61 and/or p22 from the product mixture.

### Claim 35 (depends on 34)

The method of claim 34, wherein the vertebrate cell is a mammalian cell.

### Claim 36 (depends on 35)

The method of claim 35, wherein the mammalian cell is a human cell.

### Claim 37 (depends on 36)

The method of claim 36, wherein the human cell is an HT1080 cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein the human cell is a HeLa cell.

### Claim 39 (depends on 34)

The method of claim 34, wherein the mammalian cell is a bovine capillary endothelial cell.

### Claim 40 (depends on 34)

The method of claim 34, wherein the plasminogen comprises glu-plasminogen.

### Claim 41 (depends on 34)

The method of claim 34, wherein the plasminogen comprises lys-plasminogen.

### Claim 42 (depends on 34)

The method of claim 34, wherein the isolating comprises isolating by affinity chromatography.

### Claim 43

A method for preparing A61, the method comprising combining a plasminogen with a plasminogen activator to form a mixture, incubating the mixture in an alkaline solution, thereby producing A61; and isolating the A61 from the mixture.

### Claim 44 (depends on 43)

The method of claim 43, wherein the plasminogen activator is u-plasminogen activator.

### Claim 45 (depends on 43)

The method of claim 43, wherein the alkaline solution has a pH of about 9.

### Claim 46 (depends on 43)

The method of claim 43, wherein incubating is for a period of at least about 2 hours.

### Claim 47 (depends on 43)

The method of claim 43, wherein the isolating comprises isolating by affinity chromatography.

### Claim 48

A method for preparing p22, the method comprising combining A61 with plasmin and a reducing agent to form a mixture; incubating the mixture, thereby producing p22; and isolating the p22 from the mixture.

### Claim 49 (depends on 48)

The method of claim 48 wherein the reducing agent is dithiothreitol.

### Claim 50 (depends on 48)

The method of claim 48, wherein the incubating is for at least 1 hour.

### Claim 51 (depends on 48)

The method of claim 48, wherein the incubating is at 37° C.

### Claim 52 (depends on 48)

The method of claim 48, wherein the isolating comprises isolating by affinity chromatography.

### Claim 53

A method for preparing p22, the method comprising combining A61 with plasmin and annexin II tetramer to form a mixture; incubating the mixture, thereby producing p22; and isolating the p22 from the mixture.

### Claim 54 (depends on 53)

The method of claim 53, wherein the incubating is for at least 1 hour.

### Claim 55 (depends on 53)

The method of claim 53, wherein the incubating is at 37° C.

### Claim 56 (depends on 53)

The method of claim 53, wherein the isolating comprises isolating by affinity chromatography.

### Claim 57

A method for anti-angiogenic treatment of a mammal in need thereof, the method comprising administering to the mammal an angiogenesis-inhibiting amount of an A61, p22 or a combination thereof.

### Claim 58 (depends on 57)

The method of claim 57 wherein the mammal is a human.

### Claim 59 (depends on 58)

The method of claim 58 wherein an angiogenesis-inhibiting amount of A61 is administered to the human.

### Claim 60 (depends on 58)

The method of claim 58 wherein an angiogenesis-inhibiting amount of p22 is administered to the human.

### Claim 61 (depends on 57)

The method of claim 57 wherein the A61 or p22 is a fragment of a mammalian plasminogen which aligns with human plasminogen as set forth in SEQ ID NO: 4, wherein the amino terminal amino acid aligns with Lys-78 of SEQ ID NO: 4 and the carboxy terminal amino acid aligns with Lys-180, Lys-468, or Arg471 of SEQ ID NO: 4.

### Claim 62 (depends on 57)

The method of claim 57 wherein the A61 or p22 has at least 90% identity with and the same length as a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and conservatively substituted variants thereof.

### Claim 63 (depends on 62)

The method of claim 62 wherein the A61 or p22 has a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

### Claim 64 (depends on 57)

The method of claim 57 wherein the mammal suffers from a disease selected from the group consisting of cancer, hemangiomas, acoustic neuromas, neurofibromas, trachomas, pyogenic granulomas, telangiectasias, psoriasis, scleroderma, atherosclerosis, rheumatoid arthritis, Crohn's disease, endometriosis, adiposity, pyogenic granuloma, rubeosis, and diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, retrolental fibroplasia, graft rejection, neovascular glaucoma, myocardial angiogenesis, plaque neovascularization, hemophiliac joints, angiofibroma, and wound granulation.

### Claim 65 (depends on 64)

The method of claim 64 wherein the disease is cancer and the A61, p22 or a combination thereof is administered with an anti-cancer agent selected from the group consisting of methotrexate, mitozantrone, paclitaxel, vinblastine, 5-fluoruracil, cisplatin, leucovorin, cyclophosphamide and an oncolytic virus.

### Claim 66 (depends on 65)

The method of claim 65 wherein the oncolytic virus is a reovirus, herpes virus or an adenovirus.

### Claim 67

A method for inhibiting proliferation of vascular endothelial cells, the method comprising administering to the cells an anti-proliferation amount of A61, p22 or a combination thereof.

### Claim 68 (depends on 67)

The method of claim 67, wherein the vascular endothelial cell is a mammalian vascular endothelial cell.

### Claim 69 (depends on 68)

The method of claim 68, wherein the mammalian vascular endothelial cell is a human vascular endothelial cell.

### Claim 70 (depends on 67)

The method of claim 67 wherein the A61 or p22 is a fragment of a mammalian plasminogen which aligns with human plasminogen as set forth in SEQ ID NO: 4, wherein the amino terminal amino acid aligns with Lys-78 of SEQ ID NO: 4 and the carboxy terminal amino acid aligns with Lys-180, Lys-468, or Arg-471 of SEQ ID NO. 4.

### Claim 71 (depends on 67)

The method of claim 67 wherein the A61, or p22 has at least 90% identity with and the same length as a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and conservatively substituted variants thereof.

### Claim 72 (depends on 71)

The method of claim 71 wherein the A61 or p22 has a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
